1. Home
  2. WSO vs GH Comparison

WSO vs GH Comparison

Compare WSO & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Watsco Inc.

WSO

Watsco Inc.

HOLD

Current Price

$400.95

Market Cap

16.5B

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$92.64

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WSO
GH
Founded
1945
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.5B
13.3B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
WSO
GH
Price
$400.95
$92.64
Analyst Decision
Hold
Strong Buy
Analyst Count
7
20
Target Price
$418.33
$117.80
AVG Volume (30 Days)
383.8K
1.9M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
3.26%
N/A
EPS Growth
N/A
6.74
EPS
N/A
N/A
Revenue
N/A
$982,021,000.00
Revenue This Year
$5.49
$29.73
Revenue Next Year
$5.79
$27.71
P/E Ratio
$34.24
N/A
Revenue Growth
N/A
32.88
52 Week Low
$323.05
$34.91
52 Week High
$533.07
$120.74

Technical Indicators

Market Signals
Indicator
WSO
GH
Relative Strength Index (RSI) 48.76 36.16
Support Level $400.37 $90.44
Resistance Level $430.44 $103.16
Average True Range (ATR) 14.20 5.67
MACD -3.12 -0.91
Stochastic Oscillator 18.50 16.70

Price Performance

Historical Comparison
WSO
GH

About WSO Watsco Inc.

Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue), with significant exposure in the Sun Belt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: